Home › Research › Cognitive tests and assessment
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Deschaintre Y, Richard F, Leys D, Pasquier F.. Neurology, 2009-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD).
What this study adds
Evidence grade: High
The record lists 72 participants. This observational study of 301 Alzheimer's disease patients examined whether treating vascular risk factors was linked to slower cognitive decline. Reported effect size: 69.4%; 7.0%; 25.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F. (2009). Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0b013e3181b59bf3
Vancouver
Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009. doi:10.1212/wnl.0b013e3181b59bf3. PMID: 19720973.
BibTeX
@article{deschaintre2009-19720973,
author = {Deschaintre, Y. and Richard, F. and Leys, D. and Pasquier, F.},
title = {{Treatment of vascular risk factors is associated with slower decline in Alzheimer disease}},
journal = {Neurology},
year = {2009},
doi = {10.1212/wnl.0b013e3181b59bf3},
pmid = {19720973},
url = {https://doi.org/10.1212/wnl.0b013e3181b59bf3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled.
- The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD).
- Methods We recruited 301 consecutive patients who had AD without CVD (mean age 71.7 years; 69.4% women; first Mini-Mental State Examination [MMSE] mean score 21.6; mean follow-up 2.3 years), who had attended a memory clinic between 1997 and 2003.
- VRF sought were high blood pressure, dyslipidemia, diabetes mellitus, tobacco smoking, and atherosclerotic disease.
Why it matters
This observational study of 301 Alzheimer's disease patients examined whether treating vascular risk factors was linked to slower cognitive decline. Because it is observational, it can show an association but cannot prove that treating these risk factors causes slower decline.
Study details
- Participants72
- Effect size69.4%; 7.0%; 25.7%
- Evidence strengthHigh
How this study scored 61/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 72 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 232 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.2 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 4 / 6 | Cited 13.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 2 / 4 | Cited 15 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Florence Pasquier: h-index 101 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19720973) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also in Cognitive tests and assessment
99 studies in the library are filed under Cognitive tests and assessment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Cognitive tests and assessment hub.